首页> 外文期刊>Mutagenesis >The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.
【24h】

The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.

机译:CYP17 MspA1基因多态性与乳腺癌风险:一项荟萃分析。

获取原文
获取原文并翻译 | 示例
           

摘要

Inter-individual differences in susceptibility to breast cancer are partially mediated through the levels of endogenous and exogenous steroid hormones. The CYP17 gene encodes P450c17alpha, an enzyme that is involved in the metabolism of steroid hormones. Increased endogenous steroid hormone levels have been associated with a MspA1 polymorphism in the 5'-promoter region of the CYP17 gene. The CYP17 MspA1 polymorphism has been postulated as being associated with the risk of developing breast cancer. However, the association between the CYP17 MspA1 polymorphism and breast cancer risk has been controversial in the literature. To re-examine this controversy, we have undertaken a meta-analysis of 15 case--control studies, which included a total of 4227 breast cancer cases and 4730 individual controls. The odds ratio (OR) was used to evaluate the risk of breast cancer for each study, using homozygosity of the wild-type allele as the control group. Statistical analysis showed no evidence of heterogeneity within the studies. The pooled ORs of breast cancer associated with the combined variant (A1/A2 + A2/A2) and the homozygous genotype (A2/A2) were 0.98 (95% CI 0.89--1.07) and 1.05 (95% CI 0.87--1.21), respectively. Similarly, the pooled ORs of advanced breast cancer associated with the combined variant and the homozygous genotype were 0.96 (95% CI 0.77--1.20) and 0.88 (95% CI 0.55--1.41), respectively. A pooling of the studies was also conducted for the various ethnic groups, but failed to show an association of CYP17 MspA1 polymorphism with breast cancer risk in the different ethnic groups. In addition, our results show that a possible protective effect for breast cancer risk of a later age at menarche was mainly limited to women with the A1 homozygous genotype. The OR for age at menarche (greater-than-or-equal13) was 0.87 (95% CI 0.62--1.17). Our results suggest that CYP17 MspA1 polymorphism may be at best a weak modifier of breast cancer risk but is not a significant independent risk factor.
机译:个体间对乳腺癌的敏感性差异部分通过内源性和外源性类固醇激素的水平介导。 CYP17基因编码P450c17alpha,一种参与类固醇激素代谢的酶。内源性类固醇激素水平升高与CYP17基因5'启动子区域的MspA1多态性有关。 CYP17 MspA1多态性被认为与患乳腺癌的风险有关。然而,CYP17 MspA1多态性与乳腺癌风险之间的关联在文献中一直存在争议。为了重新审视这一争议,我们对15个病例对照研究进行了荟萃分析,其中包括4227例乳腺癌病例和4730例个体对照。使用野生型等位基因的纯合性作为对照组,使用比值比(OR)评估每项研究的乳腺癌风险。统计分析表明研究中没有异质性的证据。与合并变体(A1 / A2 + A2 / A2)和纯合基因型(A2 / A2)相关的乳腺癌合并OR分别为0.98(95%CI 0.89--1.07)和1.05(95%CI 0.87--1.21) ), 分别。同样,与合并的变体和纯合基因型相关的晚期乳腺癌合并ORs分别为0.96(95%CI 0.77--1.20)和0.88(95%CI 0.55--1.41)。还对不同种族进行了研究汇总,但未能显示CYP17 MspA1多态性与不同种族中乳腺癌风险的相关性。此外,我们的结果表明,对初潮年龄较大的乳腺癌风险的可能的保护作用主要限于具有A1纯合基因型的女性。月经初潮的年龄OR(大于或等于13)为0.87(95%CI 0.62--1.17)。我们的研究结果表明CYP17 MspA1多态性可能最多只是乳腺癌风险的弱调节剂,但不是重要的独立风险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号